G L Rosner
Overview
Explore the profile of G L Rosner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
620
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meyer R, Braun R, Rosner G, Dewhirst M
Vet Anaesth Analg
. 2017 Apr;
27(2):105.
PMID: 28404033
No abstract available.
2.
Crona D, Ramirez J, Qiao W, de Graan A, Ratain M, van Schaik R, et al.
Pharmacogenomics J
. 2015 Apr;
16(1):54-9.
PMID: 25869015
The overall goal of this study was to provide evidence for the clinical validity of nine genetic variants in five genes previously associated with irinotecan neutropenia and pharmacokinetics. Variants associated...
3.
Paller C, Olatoye D, Xie S, Zhou X, Denmeade S, Eisenberger M, et al.
Prostate Cancer Prostatic Dis
. 2013 Oct;
17(1):28-33.
PMID: 24100642
Background: PSA doubling time (PSADT) is an attractive intermediate end point for assessing novel therapies in biochemically recurrent prostate cancer (BRPC). This study explores whether PSADT calculations are influenced by...
4.
Qin L, Smith B, Tsai H, Yaghi N, Neela P, Moake M, et al.
Blood Cancer J
. 2013 Sep;
3:e145.
PMID: 24013666
The ability to target myeloid leukemia with immunotherapy would represent a significant therapeutic advance. We report here immunological analysis of clinical trials of primary and secondary vaccination with K562/GM-CSF immunotherapy...
5.
Rosner G, Panetta J, Innocenti F, Ratain M
Clin Pharmacol Ther
. 2008 Apr;
84(3):393-402.
PMID: 18418374
Irinotecan, a chemotherapeutic agent against various solid tumors, is a prodrug requiring activation to SN-38. Irinotecan's complex pharmacokinetics potentially allow for many genetic sources of variability. We explored relationships between...
6.
Schuetz E, Relling M, Kishi S, Yang W, Das S, Chen P, et al.
Pharmacol Rev
. 2004 Jun;
56(2):159.
PMID: 15169924
No abstract available.
7.
Venook A, Enders Klein C, Fleming G, Hollis D, Leichman C, Hohl R, et al.
Ann Oncol
. 2003 Nov;
14(12):1783-90.
PMID: 14630685
Background: To ascertain if hepatic or renal dysfunction or prior pelvic radiation (XRT) leads to increased toxicity at a given dose of irinotecan and to characterize the pharmacokinetics of irinotecan...
8.
Maguire P, Samulski T, Prosnitz L, Jones E, Rosner G, Powers B, et al.
Int J Hyperthermia
. 2001 Jul;
17(4):283-90.
PMID: 11471980
We prospectively evaluated whether delivering a thermal dose of > 10 cumulative equivalent minutes at 43 degrees C to >90% of the tumour sites monitored (CEM43 degrees T90) would produce...
9.
Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez Jr C, et al.
J Clin Oncol
. 2001 Apr;
19(8):2142-52.
PMID: 11304766
Purpose: A pilot protocol was designed to evaluate the efficacy of fludarabine with nelarabine (the prodrug of arabinosylguanine [ara-G]) in patients with hematologic malignancies. The cellular pharmacokinetics was investigated to...
10.
Thrall D, Rosner G, Azuma C, LaRue S, Case B, Samulski T, et al.
Int J Hyperthermia
. 2000 Sep;
16(5):415-28.
PMID: 11001575
A randomized study was designed in dogs with spontaneous soft tissue sarcomas to gain information about the relationship between hyperthermia dose and outcome. The study compared two levels of thermal...